Compare Fiverr International Ltd (FVRR) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs GSK plc — how do they compare? Fiverr International Ltd trades at $8.75 (market cap $314.57M), while GSK plc trades at $50.36 (market cap $102.60B). The key difference: GSK plc is far larger — about 326.2× Fiverr International Ltd's market cap, and GSK plc pays a 3.57% dividend while Fiverr International Ltd pays none. Which is the better fit depends on your goals.
| FVRR | GSK | |
|---|---|---|
Market Cap | $314.57M | $102.60B |
Sector | Industrials | Health |
52-Week High | $26.67 | $61.18 |
52-Week Low | $8.75 | $38.22 |
Enterprise Value | $66.95M | $123.04B |
Dividend Yield | — | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $8.71, down 4.18% over 24 hours, reflecting bearish technical signals and recent earnings misses. The stock shows attractive valuation multiples with a P/E of 10.8 and P/S of 0.77, while revenue grew to $430.91M in 2025. However, Q2 2026 results missed expectations, with revenue declining 10% year-over-year due to AI disruption pressures, as reported by MarketBeat on July 29, 2026.
The outlook remains cautious with significant AI-related headwinds compressing demand for freelance services. Near-term risks include execution challenges in a shifting competitive landscape, but the current low valuation may offer contrarian appeal if the company successfully adapts its strategy.
GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.
GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
